JP2008514209A5 - - Google Patents

Download PDF

Info

Publication number
JP2008514209A5
JP2008514209A5 JP2007533908A JP2007533908A JP2008514209A5 JP 2008514209 A5 JP2008514209 A5 JP 2008514209A5 JP 2007533908 A JP2007533908 A JP 2007533908A JP 2007533908 A JP2007533908 A JP 2007533908A JP 2008514209 A5 JP2008514209 A5 JP 2008514209A5
Authority
JP
Japan
Prior art keywords
numb
cancer
patient
sample
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007533908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008514209A (ja
Filing date
Publication date
Priority claimed from GBGB0421838.4A external-priority patent/GB0421838D0/en
Application filed filed Critical
Publication of JP2008514209A publication Critical patent/JP2008514209A/ja
Publication of JP2008514209A5 publication Critical patent/JP2008514209A5/ja
Pending legal-status Critical Current

Links

JP2007533908A 2004-09-30 2005-09-20 癌マーカー Pending JP2008514209A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0421838.4A GB0421838D0 (en) 2004-09-30 2004-09-30 Cancer markers
PCT/EP2005/010153 WO2006037462A2 (en) 2004-09-30 2005-09-20 Cancer markers

Publications (2)

Publication Number Publication Date
JP2008514209A JP2008514209A (ja) 2008-05-08
JP2008514209A5 true JP2008514209A5 (https=) 2008-10-16

Family

ID=33427903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007533908A Pending JP2008514209A (ja) 2004-09-30 2005-09-20 癌マーカー

Country Status (7)

Country Link
US (1) US7901876B2 (https=)
EP (2) EP1802971A2 (https=)
JP (1) JP2008514209A (https=)
AU (1) AU2005291613A1 (https=)
CA (1) CA2581041A1 (https=)
GB (1) GB0421838D0 (https=)
WO (1) WO2006037462A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8747867B2 (en) 2004-09-30 2014-06-10 Ifom Fondazione Instituto Firc Di Oncologia Molecolare Cancer markers
US7919092B2 (en) * 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
EP2125887A4 (en) 2007-01-24 2010-11-10 Oncomed Pharm Inc COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
WO2008100563A2 (en) * 2007-02-14 2008-08-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP2010520280A (ja) * 2007-03-05 2010-06-10 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム NotchまたはNumb特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN104402998A (zh) 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
WO2010132861A2 (en) 2009-05-14 2010-11-18 Duke University Diagnostic and treatment for chronic and acute phase myeloid leukemia
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
WO2013155077A1 (en) * 2012-04-09 2013-10-17 Board Of Regents,The University Of Texas System Response markers for src inhibitor therapies
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
EP3249401B1 (en) 2015-01-22 2019-12-25 Konica Minolta, Inc. Biological substance quantitation method, pathological diagnosis support system, and program
CN109266740A (zh) * 2017-07-14 2019-01-25 中国科学院上海生命科学研究院 用于肺癌诊断或预后的标志物及诊断试剂
CN114606320B (zh) * 2022-04-13 2023-06-16 重庆医科大学 生物标志物epn3在制备诊断或评估肺癌的产品中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380777D1 (en) 1982-08-27 1989-11-30 Roger Philip Ekins Measurement of analyte concentration
WO1988001058A1 (en) 1986-08-06 1988-02-11 Roger Philip Ekins Determination of analyte concentration using two labelling markers
GB8803000D0 (en) 1988-02-10 1988-03-09 Ekins Roger Philip Determination of ambient concentrations of several analytes
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69223980T2 (de) 1991-10-15 1998-05-28 Multilyte Ltd Bindungstest unter benutzung eines markierten reagens
GB9326450D0 (en) 1993-12-24 1994-02-23 Multilyte Ltd Binding assay
GB9326451D0 (en) 1993-12-24 1994-02-23 Multilyte Ltd Binding assay
GB9404709D0 (en) 1994-03-11 1994-04-27 Multilyte Ltd Binding assay
GB9815799D0 (en) 1998-07-21 1998-09-16 Pharmagene Lab Limited Quantitative analysis of gene expression
AU768269B2 (en) * 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
FR2818747B1 (fr) * 2000-12-26 2003-05-16 Molecular Engines Laboratoires Procede de criblage base sur l'interaction siah-numb
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
JP2005500832A (ja) 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
WO2003011317A1 (en) 2001-07-25 2003-02-13 Lorantis Limited Modulators of notch signalling for use in immunotherapy
WO2003042246A2 (en) * 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
WO2003088910A2 (en) 2002-04-15 2003-10-30 Rigel Pharmaceuticals, Inc. Methods of assaying for cell cycle modulators
US20050272061A1 (en) * 2004-02-19 2005-12-08 Seattle Genetics, Inc. Expression profiling in non-small cell lung cancer
US7837993B2 (en) * 2004-03-19 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for regeneration of aged skeletal muscle tissues
US20060068434A1 (en) * 2004-09-21 2006-03-30 Jay Stoerker Methods and compositions for detecting cancer using components of the U2 spliceosomal particle
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER

Similar Documents

Publication Publication Date Title
González‐Gualda et al. A guide to assessing cellular senescence in vitro and in vivo
JP2008514209A5 (https=)
Berends et al. Biochemical and biophysical assessment of MTX‐induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan® predicts the absence of significant liver fibrosis
US10883956B2 (en) Electrochemical sensor for analyte detection
JP2021007416A (ja) 細胞全体でのアッセイおよび方法
JP2022159346A (ja) 治療剤選択のためのシグナル伝達経路活性の測定方法
Cho et al. Endometrial osteopontin mRNA expression and plasma osteopontin levels are increased in patients with endometriosis
JP2010539508A5 (https=)
RU2014112348A (ru) Способ детекции нуклеосом, содержащих гистоновые варианты
JP2014529405A5 (https=)
KR102442803B1 (ko) 결장직장암에 대한 복합 테스트
JP2019534321A5 (https=)
JP2023505526A (ja) Rasノード標的化治療剤またはrtk標的化治療剤を用いてがん患者を処置する方法
Marshall et al. Strategies for biomarker discovery in fibrotic disease
JP2018529931A5 (https=)
Fernandez et al. Tissue age affects antigenicity and scoring for the 22C3 immunohistochemistry companion diagnostic test
Ibrahim et al. Differentiating active from stable vitiligo: the role of dermoscopic findings and their relation to CXCL10
Mukherjee et al. In-cell Western™ detection of organic cation transporters in bronchial epithelial cell layers cultured at an air–liquid interface on Transwell® inserts
Devarajan The promise of biomarkers for personalized renal cancer care
Shin et al. What is the appropriate cut-off value of CRP to predict endoscopic remission in patients with ulcerative colitis in clinical remission?
Cho et al. Diagnostic and prognostic impact of osteopontin expression in endometrial cancer
Geens et al. Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy
Hu et al. From traditional biomarkers to transcriptome analysis in drug development
Huang et al. Integration of antibody array technology into drug discovery and development
Modur et al. Evidence-based laboratory medicine in oncology drug development: from biomarkers to diagnostics